Characteristics of first ROP treatment (n=173) and retreatment in association to postmenstrual and postnatal age
| Laser | Anti-VEGF | P value | |
| Treatment method, n (%) | 142/173 (82.0) | 29/173 (16.7) | <0.001 |
| PNA at treatment, median (weeks) | 12.6 (14.9 to 24.0) | 11.3 (9.6 to 24.1) | 0.001 |
| PMA at treatment, median (weeks) | 36.0 (32.4 to 47.7) | 34.1 (32.0 to 47.0) | <0.001 |
| Retreatment rate, n (%) | 46/142 (32.4) | 20/29 (69.0) | <0.001 |
| Time to retreatment, median (weeks) | 2.2 (0.9 to 12.7) | 8.3 (2.0 to 13.6) | 0.001 |
| PNA at retreatment, median (weeks) | 15.1 (11.1 to 27.6) | 19.6 (13.3 to 26.9)* | 0.001 |
| PMA at retreatment, median (weeks) | 38.6 (34.3 to 51.1) | 42.4 (36.1 to 49.3)* | 0.001 |
Values are presented as median (max and min) or n (%).
*One infant excluded receiving retreatment at PNA 86.7 weeks and PMA 109.6 weeks.
anti-VEGF, antivascular endothelial growth factor; PMA, postmenstrual age; PNA, postnatal age.